From:  Extracellular vesicles as candidate mediators linking insulin resistance and metabolic dysfunction-associated steatotic liver disease

 Operational classification of EV subclasses and their salient features in insulin resistance and MASLD.

Operational classApproximate sizePrincipal biogenesisRepresentative markersReported relevance to insulin resistance and MASLD
Small EVs (exosome-enriched)30–150 nmInward budding of the endosomal membrane forming intraluminal vesicles within multivesicular bodies; release on fusion with the plasma membraneCD9, CD63, CD81, TSG101, ALIX, syntenin-1Principal fraction studied in microRNA-mediated inter-organ signalling; adipose tissue identified as a quantitatively major systemic source
Medium and large EVs (microvesicles, ectosomes)100–1,000 nmDirect outward budding and scission of the plasma membrane; cytoskeletal and calcium-dependentAnnexin A1, integrins, tissue-specific surface antigens, exposed phosphatidylserineAmenable to flow cytometric detection, permitting phenotyping of cellular origin; hepatocyte-derived populations reported to track injury
Apoptotic bodies800–5,000 nmMembrane blebbing during apoptosisPhosphatidylserine, histones, fragmented organelles and DNAReported to increase in advanced steatohepatitis; carriers of mitochondrial DNA and other damage-associated molecular patterns
Non-vesicular co-isolatesVariableLipoproteins, protein aggregates, exomeresApolipoprotein B, apolipoprotein A-I, albuminPrincipal confounder in MASLD, dyslipidaemia increasing lipoprotein burden and potentially inflating apparent vesicle concentration and RNA yield

ALIX: ALG-2-interacting protein X; CD9, CD63, CD81: cluster of differentiation 9, 63 and 81; TSG101: tumour susceptibility gene 101.